What does a high DHEA-S mean?

Written and medically reviewed by Zahraa Sater, M.D., M.P.H.

Reviewed August 12, 2026 · Next review due August 12, 2028

Short answer

DHEA-S comes almost entirely from the adrenal glands, so a raised level points to an adrenal source of androgen rather than an ovarian one. Mild elevations occur in a minority of women with PCOS and rarely change management. The 2023 international guideline recommends measuring DHEA-S only when total and free testosterone are not elevated, noting its limited additional value.

DHEA-S, dehydroepiandrosterone sulfate, is a weak androgen made almost exclusively by the adrenal cortex. Because the ovary contributes very little, DHEA-S is used to ask where androgen excess is coming from rather than how severe it is. It is a weak hormone in its own right; most of its effect comes from conversion to testosterone in peripheral tissue. Levels fall steadily with age, so a result must be read against an age-specific reference range.

When it should be measured at all

The 2023 International Evidence-based Guideline is conservative here. It recommends total and free testosterone as the primary assessment of biochemical hyperandrogenism, and says that if testosterone or free testosterone is not elevated, clinicians could consider measuring androstenedione and DHEA-S, while noting these have limited additional value in diagnosing PCOS. Ordering DHEA-S routinely on every woman with acne produces results that are hard to act on.

What a mild elevation usually means

A modestly raised DHEA-S in a woman who otherwise fits PCOS usually reflects an adrenal contribution to the same syndrome and does not change treatment. The combined oral contraceptive pill and spironolactone work on the downstream androgen effect regardless of source. What a mild elevation does not mean is adrenal fatigue, which is not a recognised diagnosis, or a need for adrenal supplements. It also does not require imaging on its own.

The two things worth excluding

Nonclassic congenital adrenal hyperplasia is the alternative diagnosis that matters, and it is screened with an early morning 17-hydroxyprogesterone taken in the follicular phase, with an ACTH stimulation test if the screening value is borderline or raised. The Endocrine Society hirsutism guideline suggests this screening in hyperandrogenaemic women, and even in women with normal androgens where ancestry or family history raises the prior probability. The second concern is an androgen-producing adrenal tumour, suggested by a markedly high DHEA-S together with rapid onset symptoms or virilisation, which prompts adrenal imaging.

PatternInterpretationAction
Mildly raised DHEA-S, typical PCOS pictureAdrenal contribution to PCOSTreat the PCOS, no imaging
Raised DHEA-S with high 17-hydroxyprogesteronePossible nonclassic CAHACTH stimulation test
Markedly raised DHEA-S, rapid virilisationPossible adrenal tumourAdrenal imaging, specialist referral
Raised DHEA-S, no symptoms at allOften age or assay relatedRepeat against age-matched range

If a DHEA-S has come back high, bring the report with its reference range, and note whether your symptoms developed over years or over months. Those two pieces of information decide whether the next step is reassurance, a 17-hydroxyprogesterone, or imaging.

The clinical detail

Guideline positioning: 2023 recommendation 1.2.2 places androstenedione and DHEA-S as second-tier tests, considered only when total or free testosterone is not elevated, with limited additional diagnostic value. Total testosterone should be measured on a validated LC-MS/MS assay (1.2.3). All androgens are uninterpretable on a combined oral contraceptive pill (1.2.6).

For nonclassic congenital adrenal hyperplasia, the Endocrine Society hirsutism guideline recommends screening with an early morning follicular phase 17-hydroxyprogesterone in hyperandrogenaemic women, and in women with normal androgens where ancestry or family history increases risk, with ACTH stimulation testing to confirm. DHEA-S declines markedly with age, from a peak in the twenties, so age-specific reference intervals matter more than a single population range printed on a report.

Written and medically reviewed by Zahraa Sater, M.D., M.P.H.

Reviewed August 12, 2026 · Next review due August 12, 2028

Sources

  1. International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
  2. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. Endocrine Society. PMID 29522147
  3. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
  4. Polycystic ovary syndrome: an update on diagnosis and management (2026). Cleveland Clinic Journal of Medicine

Was this answer helpful?

This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.